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             Cardiovascular disease is a long term complication of diabetes, which remains a 
leading cause of mortality and morbidity. There is recent evidence for activation of renin 
angiotensin system (RAS) in diabetic animals and humans. Emerging evidence shows that 
the vasoconstrictor actions of Ang II may be opposed by formation of vasodilator, Ang (1-7). 
There is limited data on blood pressure in murine models of type 2 diabetes. The aim is to 
study the role of angiotensin converting enzymes ACE and ACE2 in diabetes induced 
cardiovascular dysfunction using type 2 diabetic murine mouse models (db/db mice). Mice 
were implanted with carotid telemetric probes for chronic monitoring of MAP, heart rate and 
activity. At 8-9 weeks age, mice showed hyperinsulinemia, hyperglycemia and increase in 
body weight compared to their lean controls while MAP was not altered. At an older age (14-
15 weeks) there was a significantly increased BP in the db/db mice compared to controls. In 
young (8 weeks) normotensive mice there was a highly significant increase in plasma ACE 
activity in db/db mice compared to controls. In contrast there was increased ACE2 activity 
and decreased ACE activity in kidney in 8weeks old db/db mice compared to controls. No 
significant difference between ACE and ACE2 activity was observed in lungs and brain. In 





a significant increase in kidney ACE2 and decrease in kidney ACE protein expression in 8 
weeks old db/db mice compared to their lean controls. In addition no difference was 
observed between lung ACE and ACE2 protein expression. Increased plasma and kidney 
ACE activity and a decreased kidney ACE2 activity were observed in 24 weeks old db/db 
mice. In conclusion: 1. Despite an increase in plasma ACE activity in young (8 weeks) db/db 
mice they were normotensive 2. There was an age dependent increase of BP in db/db mice. 
 3. ACE2 may play a compensatory mechanism against development of hypertension in 
db/db mice in the early stage of type2 diabetes. 4. The up regulation of ACE coupled with a 
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Type 2 diabetes 
Diabetes is occurring at an epidemic rate in the United States and other western countries 
(Mokdad et al. 2000). The pathology of diabetes is characterized not only by 
hyperglycemia but also by hypertension, dyslipidemia, microalbuminaria and 
inflammation (Sowers and Stump 2004a). Since up to 75% of cases of cardiovascular 
disease (CVD) in patients with diabetes can be attributed to hypertension, aggressive 
management of elevated blood pressure (BP) is essential for reduction in cardiovascular 
morbidity (Sowers and Stump 2004a). For example, recent clinical trials demonstrated 
that strict glycemic control in patients with type 2 diabetes correlates with a reduction in 
cardiovascular complications (Horio et al. 2004). The patients at risk for diabetes also 
present higher baseline serum glucose concentration, increased body index, elevated 
systolic blood pressure and reduced serum high-density lipoprotein-cholesterol 
(Lindholm et al. 2002a)}.  
Diabetes and hypertension 
Diabetes and arterial hypertension frequently coexist (Genuth 2006), and it is well known 
that patients presenting with both disorders have increased antihypertensive drug 
requirements to achieve the recommended goals of blood pressure control and elevated 
cardiovascular risk (Alderman 2004). The connection between diabetes and 
cardiovascular disease is profound and clinically extraordinarily important. Among 
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people with diabetes, type 2 diabetes specifically, the major cause of death is 
cardiovascular disease (Chobanian et al. 2003). The global mortality attributable to 
diabetes in the year 2000 was estimated at 2.9 million deaths, representing 5.2% of all 
deaths globally (Jacob 1999). These figures are expected to increase, with the prevalence 
diabetes worldwide predicted to rise from 4 % in 1995 to 5.4% by the year 2025, by 
which time it is estimated that there will be around 300 million adults with diabetes 
globally (Horio et al. 2004). Diabetes and hypertension independently predispose to renal 
and cardiovascular complications (Campbell 1987). Despite the importance of the 
relationship between diabetes and cardiovascular disease, little is known about the 
biologic basis of this association (Chobanian et al. 2003).  
Hypertension affects 20-60 % of the individuals with diabetes (Wingard et al. 1983). The 
prevalence of hypertension in diabetic population is 1.5 to 3 times higher than that of 
non-diabetic groups. In type 1 diabetes, hypertension usually occurs in association with 
nephropathy whereas in type 2 diabetes, it may be present at early diagnosis stage, as a 
part of the metabolic syndrome (Campbell 1987). Hypertension is twice as common in 
the type 2 diabetic, compared with the nondiabetic; it is present in 85% of subjects with 
nephropathy , and the coexistence of these two conditions is associated with an increase 
in the risk of retinopathy, renal failure, and cardiovascular disease (CVD)(Chen et al. 
2005).  An increase of 5 mm Hg in systolic or diastolic blood pressure increases the risk 
of CVD by 20% to 30%; a diastolic blood pressure above 70 mm Hg increases the risk of 
retinopathy; and end-stage renal disease is 5 to 6 times more common in the hypertensive 
diabetic patients (Carey et al. 2001). 
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Already in the diabetic setting, agents that interrupt the renin-angiotensin system and 
increasingly also the aldosterone pathway appear to be particularly useful in diabetic 
renal and cardiovascular disease (Pitt et al. 2001). Hypertension in diabetic patients has 
to be controlled to reduce the occurrence of macro vascular complications of diabetes. 
Observational studies show that people with both diabetes and hypertension have 
approximately twice the risk of cardiovascular disease as non-diabetic people with 
hypertension. In addition to its role in macro vascular complications, hypertension greatly 
increases the risk of renal insufficiency and diabetic nephropathy (Wingard et al. 1983).  
People with diabetes are two to four times more likely to suffer strokes and once having 
had a stroke, are two to four times as likely to have a recurrence (Mokdad et al. 2000). 
Deaths from heart disease in women with diabetes have increased 23 percent over the 
past 30 years compared to a 27 percent decrease in women without diabetes. Deaths from 
heart disease in men with diabetes have decreased by only 13 percent compared to 36 
percent decrease in men without diabetes (Mokdad et al. 2000). Diabetes is a leading 
cause of death in the United States of America (USA).   Based on the statistics in the year 
2007, diabetes contributed to approximately 224,092 deaths (Brenner et al. 2001). In the 
year 2007, the total estimated economic costs spent on type2 diabetes were 
approximately $132 billion.  There are 20.8 million children and adults in the United 
States, or 7% of the population, who have diabetes (Mokdad et al. 2001). While an 
estimated 14.6 million have been diagnosed, unfortunately, 6.2 million people (or nearly 




Renin-Angiotensin system (RAS) 
The implication of the renin-angiotensin system (RAS) in the regulation of the 
cardiovascular system has been well known for many years (Brosnihan et al. 2003;Carey 
et al. 2000). Accordingly, many medications have been developed to treat several 
pathologies, e.g. diabetes related hypertension, hypertension and heart failure and RAS is 
emerging as one of the major target in the treatment of cardiovascular diseases 
(Danilczyk et al. 2003).Therefore, the whole dynamic of RAS has to be evaluated. In this 
project the main emphasis will be on RAS and its enzyme components ACE (Angiotensin 
converting enzyme) and ACE2 (Angiotensin converting enzyme 2) and their specific 
effect in diabetes related hypertension offering a new perspective on this potential target 
for the treatment of cardiovascular diseases and hypertension. A better understanding of 
the mechanisms of RAS will open new horizons for novel drug therapy by RAS 
inhibition in treating type 2 diabetes worldwide (Crackower et al. 2002). The importance 
of the Renin-Angiotensin system (RAS) and the pivotal role of angiotensin II (Ang II) in 
the pathogenesis of hypertension and other cardiovascular diseases is widely investigated. 
(Ferrario and Chappell 2004). The RAS has long been recognized to play a crucial role in 
the regulation of blood pressure and electrolyte balance. It is an enzymatic cascade 
reaction. The processing scheme begins with the conversion of angiotensinogen (AGT) to 
angiotensin I (Ang I) via renin (de et al. 2000;Peach 1977). Ang I has little or no 
biological activity but is converted across vascular beds, particularly in the lungs, to the 
octapeptide Ang II (Carey et al. 2001).  Angiotensin converting enzyme (ACE) plays a 
central role in the scheme; it catalyzes the cleavage of the C-terminal dipeptide (L-
histidyl-L-leucine) from the inactive decapeptide Ang I, to produce potent 
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vasoconstrictor Ang II. The traditional view that Ang II is the key product of RAS has 
been questioned with the discovery of angiotensin converting enzyme 2 (ACE2), as well 
as growing evidence for a physiological role for Ang (1-7)) (Donoghue et al. 
2000;Tikellis et al. 2003).  ACE2 converts Ang I to Ang 1-9, which can be further 
hydrolyzed by ACE to form Ang 1-7(Ferrario and Chappell 2004). ACE2 also catalyses 
the generation of Ang 1-7 by removal of a COOH-terminal amino acid from Ang II 
(Tipnis et al. 2000;Vickers et al. 2002b). The putative product of ACE2, Ang 1-7, is a 
potent vasodilator and mediates effects opposite to those of Ang II in several tissues 
(Ferrario and Chappell 2004).  
 
Angiotensin Converting Enzyme (ACE) 
 ACE was discovered in plasma in 1956 by Leonard T. Skeggs (Skeggs, Jr. 1993). ACE 
is also present in other organs such as kidney, heart, pancreas, and brain. ACE is a 
monomeric, membrane bound, zinc and chloride dependent di-peptidyl carboxypeptidase. 
ACE is an important therapeutic target for the management of hypertension during 
diabetes (Lieberman et al. 1986). Inhibitors of ACE that reduce the formation of Ang II 
have been highly successful in the management of hypertension in type 2 diabetes. 
Pathological activation of tissue ACE with resulting increase in local Ang II produces 
deleterious effects on the kidney and the heart during organ remodeling,  
ischemic injury and restenosis (Ferrario and Chappell 2004).  The kidney, under the 
regulation of Ang II (produced by ACE) and aldosterone, maintains the electrolyte 
balance in the body. In rats, there was dramatic increase in ACE associated with 
development of hypertension (Crespo et al. 2003). The present study of increased ACE 
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expression revealed that higher ACE was associated with an increased diabetic 
pathology, in terms of renal function and blood pressure (Fernandez et al. 2003). 
 
Angiotensin converting enzyme 2 (ACE2) 
ACE2, a recently identified homologue of ACE, represents a new potentially important 
target in cardiovascular disease in type2 diabetes. ACE2 was identified and cloned 
recently by Donoghue et al and Tipnis et al and was described in kidney, heart and the 
testis. ACE2 also expresses in the brain, pancreas, lungs and other tissues (Brosnihan et 
al. 2003;Ferrario and Chappell 2004).  There is no evidence for the presence of ACE2 in 
the plasma or circulating ACE2. Previous studies have shown that ACE2 knock-out mice 
had an elevation of plasma Ang II levels, supporting the hypothesis that ACE2 provides 
an alternative pathway for Ang I and Ang II degradation (Carey et al. 2001). The 
vasoconstrictor actions of Ang II may be opposed by the formation of Ang (1-7). ACE2 
converts Ang II into Ang (1-7) with a higher catalytic efficiency than any other known 
Ang (1-7) forming enzyme. The reported potential involvement of ACE2 in both Ang II 
degradation and Ang (1-7) production add another arm of complexity to the RAS. Ang 
(1-7) binds to a non-Ang II type 1/Ang II type 2 receptor originally defined as the Mas 
oncogene and mediates functions that oppose the actions of Ang II (Santos et al. 2003). 
ACE2 displays 42% amino acid identity to ACE and, like ACE, is a type I integral 
membrane protein that can be proteolytically shed from the plasma membrane. More 
recently, ACE2 has gained considerable attention as being a receptor for the corona virus 
that causes severe acute respiratory syndrome (SARS) and as being protective against 
severe acute lung failure (Muller-Wieland et al. 1998). ACE2 is not inhibited in any way 
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by the ACE inhibitors, captopril and lisinopril {Wysocki, 2006 378 /id.  Importantly, 
ACE2 not only controls angiotensin II levels but functions as a protease on additional 
molecular targets that could contribute to the observed in vivo phenotypes of ACE2 



















            
            
    
 




Diagram 1: A schematic representation of the Renin-Angiotensin system cascade 
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Crackower et al. reported that several hypertensive animal models exhibit reduced ACE2 
expression in the kidney and that the ACE2 knockout mice exhibit severe 
glomerulosclerosis (Crackower et al. 2002). Despite the growing evidence that ACE2 is a 
component of the RAS, the influence of ACE2 on angiotensin metabolism within the 
kidney of other tissues is not well known, particularly in animal models.  In the human 
kidney, ACE2 was described in the proximal tubule epithelial cells. Additionally, 
conflicting results have been reported in renal pathologies, such as diabetic nephropathy 
in humans and rodents, suggesting both an increase and decrease in ACE2 protein (Ye et 
al. 2004). Tikellis et al were the first to report that ACE2 expression were reduced in the 
kidneys of rats with longstanding diabetes mellitus (Tikellis et al. 2003), whereas more 
recently, Ye et al, and Wyoscki et al, reported that there was an early increase in ACE2 
expression and activity in db/db diabetic mice (Wysocki et al. 2006;Ye et al. 2004). 
 
There is no evidence for the presence of ACE2 in the plasma (Elased, 2005 1 /id). In a 
previous human study it has been shown that circulating ACE2 was ~ 100- fold lower 
than ACE and was detectable in only 40 subjects (Rice et al. 2006). In this project we 
planned to investigate for detectable levels of ACE2 in plasma.  There is no data related 
to blood pressure values in these mice at an early and later stage of type 2 diabetes. The 
rationale for the present study was twofold: first, activation of RAS plays an important 
role in the development of experimental and clinical diabetes induced hypertension, and 




Local Ang II constricts the efferent glomelular arterioles thereby maintaining the 
glomelular filtration rate, and preserves the filtration function of the kidney during 
changes in the blood pressure (BP) (Bruemmer et al. 2003;Li and Ren 2006). An 
increased ACE2 activity increases Ang (1-9), which in turn may compete with Ang I for 
ACE thereby having an additional effect on the decrease of Ang II formation (Turner et 
al. 2002). 
 
The primary function of RAS is to maintain homeostatic blood perfusion particularly 
during conditions of blood volume depletion or in the presence of hypotensive stimuli. 
This is accomplished by AngII’s regulation of arterial pressure by stimulating 
sympathetic tone, vasoconstriction and secretion of aldosterone that leads to sodium and 
water retention by the kidney (Hummel et al. 1966). However, the loss of RAS’s 
homeostatic balance induces hypertension that is associated with cardiovascular and renal 
diseases such as heart failure, hypertrophic remodeling, myocardial infarction (MI), 
atherosclerosis and nephrosclerosis (Hummel et al. 1966). Some of the most compelling 
evidence for RAS involvement in hypertension comes from genetic manipulation of its 
constituents. Mice lacking key components of this system such as renin, ACE, AGT or 
the AT1 receptors have greatly advanced our knowledge of the RAS and confirmed its 
role in BP control since these mutants all show reduced BP (Jacob 1999;Shiuchi et al. 
2004). 
 
The balance between Ang II and Ang (1-7), reflecting ACE and ACE2 activities, 
respectively, is to be considered as physiologically significant ratio (Huentelman et al. 
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2004). Over reactivity of the renin-angiotensin system (RAS) has been identified as an 
important determinant that is implicated in the etiology of diabetes, heart disease and 
therefore represents a major target for therapy (Parving et al. 2001).  
 
Angiotensin II is the main effector hormone of the renin-angiotensin system (RAS), 
which regulates blood volume, arterial pressure, and cardiac and vascular function. Ang 
II binds to two distinct receptors, type I (AT1) and type II (AT2) (Ferrario et al. 2005b). 
The Ang AT1 receptor mediates most of the known physiological and pathophysiological 
actions of Ang II in renal, cardiovascular and neuronal systems (Campbell 1987). Ang II 
also binds to AT1 and AT2 receptors, inducing a counter-regulatory vasodilatation that is 
largely mediated by bradykinins (BK) and nitric oxide (NO) (Carey et al. 2001). 
 
There is clinical data to document the effectiveness of using ACE inhibitors and 
Angiotensin receptor blockers (ARB) in diabetics (Shinozaki et al. 2004). There is 
evidence that ACE levels are increased in diabetic animal models and that ACE inhibitors 
and ARBs (AT1 receptor blockers) lower blood pressure and improves the kidney 
function (Guo et al. 2005a). Recent comparative trials in patients with type2 diabetes and 
hypertension have suggested that AT1 receptor antagonists may be superior to all other 
alternative antihypertensive agents (Chu et al. 2006a). 
 
Losartan (AT1 antagonist) treatment in some animal models has improved the sensitivity 
to insulin. However, there is no information on the specific role of Ang AT1a receptors in 
controlling the blood pressure (Shinozaki et al. 2004). There is very little information as 
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to the mechanisms by which AT1 receptor blockers like losartan produce reduction in 
blood pressure and have control on the chronic cardiovascular changes in mice during 
type2 diabetes mellitus. There is clinical data to document the effectiveness of ACE 
inhibitors and Ang receptor blockers (ARB) in diabetics (Gilbert et al. 2003). In addition, 
long term treatment with losartan lowered the risk of developing diabetes (Lindholm et 
al. 2002b). A general role for the RAS in diabetes-induced hypertension is supported by 
the depressor effects of ACE inhibitors and ARBs in rats (Stubbs et al. 1994). In a recent 
clinical trial candesartan appears to prevent diabetes in heart failure patients, suggesting 
that the RAS is implicated in glucose regulation (Yusuf et al. 2000). 
 
A better understanding of the protective effects of RAS inhibition on type 2 diabetes is of 
profound importance to human health, given the massive rise in the incidence of type2 
diabetes and related cardiovascular problems worldwide (Chu et al. 2006b). It is for this 
reason that we used animal models to study the evolution of hypertension in diabetic 
mice in relation to changes in blood glucose, insulin and indices of the RAS 
 
Animal models of type2 diabetes (db/db mice) 
In the present study we used the db/db genetic mouse model that has a point mutation in 
the diabetes (db) gene encoding the leptin receptor gene (Coleman 1983). At early stages, 
they serve as a good model for type 2 diabetes, characterized by hyperinsulinemia, and 
progressive hyperglycemia (Coleman and Hummel 1974). Although there are several 
reports of vascular hyperreactivity in db/db mice(Sowers and Stump 2004b), there is 
limited and conflicting data on the in vivo cardiovascular changes in these models. 
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Recently there are reports of increased (Bagi et al. 2005), decreased (Kosugi et al. 2006) 
or no change in BP in db/db mice (Moriyama et al. 2004). However, cardiovascular 
studies in these genetic models are limited with little information on data on indices of 
the RAS. We conducted comprehensive cardiovascular studies to establish the role of 
diabetes in triggering an increase in BP and changes in other cardiovascular parameters in 
db/db diabetic mice. 
 
A major role for the local RAS in the development and progression of diabetic 
nephropathy has been clearly demonstrated (Brenner et al. 2001). Although ACE2 
expression seems to be down regulated in diabetes induced kidney disease, there is 
evidence suggesting that ACE2 expression is increased in early phases of diabetes in the 
absence of renal injury (Ye et al. 2004). It has been shown previously that the 
significantly increased ACE2 activity and expression in young (6-8 weeks) db/db mice 
might be the cause for renal protection at that early stage (Ye et al. 2004). But there is 
limited data on the blood pressure and heart rate in these young mice. Thus, it would now 
be of interest to specifically examine the ACE2 levels in young and old mice in relation 
to the changes in cardiovascular parameters. Previous data suggests that in mice, early 
development of diabetes paralleled increased ACE2 protein expression in the renal 
cortical tubules while ACE expression is decreased ACE2 might be renoprotective in 
early stages of type 2 diabetes (Ye et al. 2004).  
 
 There is much information to show that the RAS is critical in regulation of blood 
pressure, water balance and endocrine secretion. Nevertheless, there are questions as to 
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exact mechanisms by which RAS functions, particularly as to the relationship between 
ACE and ACE2 in the regulation of cardiovascular parameters in murine models of type2 
diabetes. To close this knowledge gap we studied the role of ACE and ACE2 in diabetes 
induced hypertension with a particular focus on the newly discovered component of 






















The objective of this project is to study the changes of blood pressure in relation to 
changes in ACE/ACE2 balance in murine models of type 2 diabetes. For this project we 
have used (db/db) mice as type 2 diabetic murine models. Another goal is to investigate 
the role of Ang AT1 receptors in the development of cardiovascular dysfunction in 
diabetic (db/db) mice. Radio telemetric probes were inserted in 8-9 weeks old db/db mice 
and blood pressure was monitored 14-15 weeks. To investigate the role AT1 receptor in 
diabetes induced hypertension, mice were treated with losartan (10 mg/kg/day for 12 
weeks) and cardiovascular parameters were measured. In addition, ACE and ACE2 
enzyme activities and protein expression were measured in young (8 weeks) and old (24 
weeks) db/db mice. The concurrent measurement of ACE and ACE2 activity should be 
helpful in the evaluation of tissue specific alterations of these two enzymes, involved in 













Hypothesis and Specific aims 
Hypothesis 
The hypothesis of this proposal is that cardiovascular complication of diabetes such as 




1. To test the hypothesis that there is an increase in blood pressure (BP) 
during the course of diabetes in db/db mice. (Cardiovascular parameters were 
measured in young and old db/db mice by radio telemetry). 
2. To test the hypothesis that there is up regulation of ACE and down 
regulation of ACE2 in db/db mice which contributes to the high blood pressure at 
a later stage of diabetes (ACE1 and ACE2 enzyme activity and protein expression 
were measured in normotensive and hypertensive db/db mice and their lean 
controls). 
3. To investigate the role of  AT1 receptor on blood pressure in db/db mice. 
Eight weeks old db/db mice were treated with losartan and cardiovascular 





Materials and methods 
Animals: 
Genetically diabetic male 7-8 weeks old BKS.Cg-m +/+ Lepr db/J (db/db) mice and their 
age matched non-diabetic littermates were used for the experiments. The animals were 
obtained from the Jackson Immunoresearch Laboratory (West grove, PA). Animals were 
housed individually at 22°C at room temperature with a 12:12-h light/dark cycle (0600 h 
– 1700 h, lights on) with ad-libitum access to water and standard mouse chow. All 
experimental protocols were approved by the WSU Animal care and Use Committee. 
 
                                
 
Lean Control mice Obese diabetic mice 
 
 




1. Measurement of cardiovascular parameters: 
 Radio telemetry is a direct method of blood pressure. It is the method preferable for 
long-term recording of blood pressure and heart rate. Radio telemetric measurement of 
mouse blood pressure, while initially invasive, has been shown to accurately monitor 
systolic pressure, diastolic pressure, heart rate, and loco motor activity. For the surgical 
procedure, mice were anesthetized with ketamine/xylazine (120:20 mg/kg, im). Radio 
telemetric catheters (model TA11PA-C10, Data Sciences International, St. Paul, MN) 
were inserted into the left common carotid artery, with the transmitter body positioned 
subcutaneously on the right flank. Recordings were made after the mice had fully 
recovered from surgery (6-7 days). Continuous 24 hours recordings of the blood pressure 
(BP) and heart rate (HR) were made every week after the mice had fully recovered from 
surgery (5-7 days). Locomotor activity was also recorded by radio telemetry which 
detects animal movement.  
 
 
2. Chronic treatment with losartan: 
 
Eight week old obese db/db mice were randomly assigned to losartan dose groups. Each 
group consisted of 6–8 mice. The mice received 10 mg · kg–1 · day–1 of losartan dissolved 
in their drinking water for 12 weeks.  An additional two groups of age-matched control 









3. Measurement of blood glucose levels:  
Blood glucose samples were determined using an Accu – Check Advantage Blood 
Glucose Monitor (Roche Diagnostic Corporation, Indianapolis, IN). Blood glucose 
samples were taken from a cut made on the tail vein. Blood glucose is expressed in 
mg/dl.  
4. Collection of tissue and plasma samples: 
Mice were decapitated and trunk blood was collected in ice-chilled heparinized tubes. 
Blood was centrifuged at 10,000 x g for 10 mins. The supernatant clear plasma was 
immediately separated and stored frozen at -80°C for future use. Kidney, brain, liver, 
pancreas, and lungs were quickly removed, frozen in liquid nitrogen and stored at -80°C 
for enzyme activity assays. Tissues were homogenized on ice in 1:9 (w/v) of Tris Hcl (50 
mM, pH 7.4) containing 2 mM PMSF. The homogenate was centrifuged at 10,000 x g for 
10 min to remove cellular debris. Total protein content was determined in the supernatant 
using the Bradford protein assay with BSA as a standard (BioRad Protein Assay Reagent, 
BioRad Labs, Hercules, CA).  
 
5. Measurement of plasma insulin levels: 
Insulin levels were measured in 10µl aliquots of plasma in db/db and control mice using 
Insulin ELISA Immunoassay kit from Linco Research Ltd, CA.  The absorption at 450 
nm and 590 nm was read in a FusionR Packard plate Reader. The final concentration of 
plasma insulin was expressed in ng/ml of plasma. 
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6. Measurement of ACE activity:  
ACE activity assays were performed using an assay kit purchased from ALPCO 
Diagnostics (Windham, NH, USA). In minin tubes 10 µl plasma or tissue extracts (50-
100 µg) were incubated with 100 µl of  HEPES buffer (pH 8) containing the synthetic 
substrate H³ hippuryl glycine glycine (H³ Hip-Gly-Gly) at 37º C in a constant shaking 
water bath . After 60 min incubation the reaction was terminated by adding 50 µl of 1 N 
hydrochloric acid solution. Liberated H³-Hippuric acid due to ACE activity in samples 
was separated from unreacted substrate by addition of 1.5 ml of scintillant cocktail (from 
the kit) and measured in a beta counter (Packard 1800TR Liquid Scintillation Analyzer). 
ACE activity was expressed in units/µg protein used as previously described. (Neels et al. 
1982)  One unit (U) of angiotensin converting enzyme activity is defined as the amount 
of enzyme required to release 1 µmol of hippuric acid per minute per litre of plasma at 
37º C under the assay conditions described (i.e. U/ml = kU/L =  µmol/litre per hour). 
 
 7. Measurement of ACE2 activity 
ACE2 activity was measured using two flouregenic substrates, 7-Mca-YVADAPK [Dnp] 
purchased from (R&D sys Inc, Minneapolis, MN) and 7-Mca-APK [Dnp] purchased from 
(BIOMOL systems, Plymouth meeting, PA), as described before (Vickers et al. 
2002a;Wysocki et al. 2006) with some modifications. Cleavage of this substrate by 
ACE2 removes the 2, 4-dinitrophenyl moieties that quench the fluorescence of the 7-
methoxy-coumarin moiety, thus resulting in increased fluorescence (Vickers et al. 
2002a). The specificity of the ACE2 enzyme activity assay was determined using kidney 
extract from ACE2 Knockout (KO) mice. ACE2 flouregenic activity assays were 
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performed with final concentration of 100µM flouregenic substrate in total volume of  
100 µl of the ACE2 assay buffer (75 mM Tris buffer, 300mM NaCl, 10 µM of Zinc 
Chloride, pH-7.4). Reactions were initiated by the addition of tissue extract at room 
temperature and carried out for 2 or 18 hours. The liberated fluorescence was read at an 
excitation wavelength = 328 nm and emission wavelength = 393 nm (FusionR Packard 
plate reader). The reaction products (fluorescence units) were quantified by using a 
standard solution of Mca and ACE2 activity was expressed as pmoles of Mca / hr/ 
microgram of protein as previously described(Vickers et al. 2002a).  
 
8. Western Blot Analysis of ACE and ACE2: 
Kidney, brain and lungs from control and diabetic mice were quickly removed and 
homogenized on ice in lysis buffer containing protease inhibitors and EDTA (Complete, 
Minin, EDTA Tablet, Roche Diagnostics, Mannheim, Germany). Tissue homogenate was 
centrifuged at 10,000 x g for 10 min to remove cellular debris. Total protein content was 
determined in the supernatant using the Bradford protein assay with BSA as a standard 
(BioRad Protein Assay Reagent, BioRad Labs, Hercules, CA). Samples were mixed with 
25 µl Laemli loading buffer (4% SDS, 100 mmol Tris-Cl, pH 6.8, 20% glycerol, 0.2% 
bromophenol blue, and 200 mmol/L dithiothreitol) and boiled for 10 minutes. Twenty 
miclolitre (30-50 µg protein per lane) were be loaded onto a 10% sodium dodecylsulfate 
(SDS) –tris-glycine polyacrylamide gel and separated by electrophoresis. Subsequently, 
protein were electro transferred  onto a  PVDF membrane in transfer buffer (20Mm Tris, 
150mM Glycine, 400 ml Methanol) for 2 hr. The PVDF membranes were blocked for 1 
hour in 10% non-fat dry milk solution in 2 % Tween-PBS. For analysis of ACE the 
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membranes were probed with primary monoclonal mouse anti- ACE (1:200, Chemicon 
International ltd, Temecula, CA) for 3 days at 4ºC. The membrane was then washed in 
Tween-PBS, and incubated with secondary antibody HRP-conjugated donkey Anti-
Mouse IgG (1:40000; Jackson immunoresearch Laboratories, PA). For analysis of ACE2, 
the membranes were probed with primary polyclonal rabbit anti-ACE2 (1:200, Santa 
Cruz biotechnology Ltd, Santa Cruz,) for 3 days at 4ºC. The membrane was then washed 
in 2% Tween-PBS, and incubated with secondary antibody HRP-conjugated donkey 
Anti-rabbit IgG (1:40000; Jackson immunoresearch Laboratories, PA) for 2 hours and 
washed (3*15 minutes TBST). Blots were detected using an enhanced 
chemiluminescence and visualized using Fuji film image analyzer (LAS 3000 image 
Quant, Sunnyvale, CA). The ACE and ACE2 bands were visualized at an apparent 




Results are expressed as means ±SEM for all groups. When only two groups were 
compared in this project, the probalities of chance differences between the experimental 
groups were calculated with Student’s unpaired two tailed t test. When two same groups 
of animals are considered then a Student’s paired two tailed t test was done. For all the 
comparisons, P<0.05 was considered to be statistically significant. For multiple 
comparisons between two or more groups ANOVA was done to check whether the 































































































Figure 1: Mean arterial pressure (MAP) and heart rate (HR) in young (8 weeks) db/db 
diabetic mice. MAP and HR were recorded in young db/db mice and their age 
matching control mice in both light and dark periods (*P<0.01 control vs. 


























































Figure 2: Mean arterial pressure (MAP) and heart rate (HR) in (12-13 weeks old) db/db 
mice. MAP and HR were recorded in 12-13 weeks old db/db mice and their age 
matching controls in both light and dark periods (*P< 0.01 control vs. diabetic, 





































Figure 3: Effect of chronic treatment with losartan on blood pressure in old (20 weeks) 
db/db diabetic mice. 8 weeks old db/db diabetic mice and their lean controls were 
treated with AT1 antagonist, losartan (10 mg/kg/day) for 12 weeks (*P<0.01 





























































Figure 4: Plasma insulin level and blood glucose levels were measured in the db/db mice 
and their lean controls at 8-9 weeks of age (*P<0.01 control vs. diabetic, n=6). 













































Figure 5: Age dependent increase in blood glucose in db/db diabetic mice. Blood glucose 
was measured in db/db mice and their lean controls from 7-35 week (*P<0.01 









4.5 ± 0.8 *550 ± 25 *35.5 ± 1.2 *14Diabetic db /db
1.2 ± 0.25117.1 ± 0.525.4 ± 0.314Lean Control
27.17 ± 2.02 *315 ± 27.9 *33.5 ± 1.1 *8Diabetic db /db












Table 1: Age dependent changes in body weight, blood glucose and plasma insulin 
levels. Body weight, blood glucose and plasma insulin was measured in 8 weeks 
and 14 weeks old db/db mice and their lean controls. (*P<0.01 control vs. 





























Figure 6: ACE2 activity assay using Mca-YVADAPK [Dnp] substrate. Plasma (10 μl), 
and tissue extracts (50 μg protein) from ACE2-WT and ACE2- KO were 
incubated with Mca-YVADAPK [Dnp] substrate and ACE2 activity was measured 
































Figure 7: Effect of NaCl on ACE2 activity using ACE2 flouregenic substrate Mca-APK-
[Dnp]. ACE2 activity was measured in kidney extract (50 μg protein) with 

































Figure 8: Kidney ACE2 activity using Mca-APK [Dnp] substrate. Kidney extracts (50 μg 
protein) from was incubated with Mca-APK [Dnp] substrate in presence and absence of 
100 mM EDTA. To validate the assay kidney lysate from ACE2 KO was incubated in 































      Figure 9:  Brain ACE2 activity in db/db diabetic mice (B) and their lean controls (A) 
using 7-Mca-APK [Dnp] as substrate in the presence and absence of selective ACE 
inhibitor (captopril, 100 μM) and selective ACE2 inhibitor, (DX-600, 10 μM). Each bar 

































































Figure 10: Effect of time on ACE2 activity using Mca-APK [Dnp] as substrate in plasma, 






























Figure 11: Plasma ACE and ACE2 activities were determined in 8 weeks old db/db mice 
and their controls. (*P<0.01 control vs. diabetic, n=6). The minimum detectable 






































































































Figure 12: Kidney ACE activity and ACE2 enzyme activities were measured in kidney 
extract (50 μg protein) from 8-9 weeks old db/db diabetic mice and their age 























































Figure 13: Lung ACE and ACE2 enzyme activities were measured in lungs extract (50 μg 
protein) in 8-9 weeks old db/db diabetic and their age matched lean controls. 




















































Figure 14: Brain ACE and ACE2 enzyme activities were measured in brain extract (85.5 
μg protein) in 8-9 weeks old db/db diabetic and their lean controls. Values are 


































Figure 15: Summary of ACE activity in plasma, kidney, brain and lung tissue extracts 
from 8 weeks old db/db diabetic mice and their lean controls (*P<0.01, control vs. 




































Figure 16: Summary of ACE2 activity in plasma, kidney, brain and lung tissue extracts 
from 8 weeks old db/db diabetic mice and their lean controls (*P<0.01, control vs. 
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Figure 17: Western blot analysis of kidney ACE protein expression in 8 weeks old db/db 
mice and their lean controls. Kidney ACE band (top panel) at 170 kDa band was detected 
by ACE antibody using β-actin (bottom panel) as an internal standard (*P<0.01 control 
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Figure 18: Western blot analysis of kidney ACE2 protein expression in 8 weeks old 
db/db mice and their lean controls. Kidney ACE2 band (top panel) at 90 kDa band was 
detected by ACE2 antibody using β-actin (bottom panel) as an internal standard (*P<0.01 
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Figure 19: Western blot analysis of lung ACE protein expression in 8 weeks old db/db 
mice and their lean controls. Lung ACE band (top panel) at 170 kDa band was detected 
by ACE antibody using β-actin (bottom panel) as an internal standard. Values are 























































Figure 20: Western blot analysis of lung ACE2 protein expression in 8 weeks old db/db 
mice and their lean controls. Lung ACE2 band (top panel) at 90 kDa band was detected 
by ACE2 antibody using β-actin (bottom panel) as an internal standard. Values are 


































Figure 21: Increased kidney ACE activity in the old (24 weeks) hypertensive db/db mice. 
ACE activity was determined in the kidney by using radioactive 1H³ tritiated hippuryl 
glycine in young db/db mice. There was a significant increase in kidney ACE activity 


































Figure 22: Decreased kidney ACE2 activity in the old (24 weeks) hypertensive db/db 
mice. ACE2 activity was determined in the kidney by using flouregenic substrate 7-Mca-
APK-[Dnp] in young (8 weeks) and old db/db mice (26 weeks) (*P<0.01, Control vs. 












































Figure 23: Increased plasma ACE activity in the old (24 weeks) hypertensive db/db 
mice. ACE activity was determined in plasma by using radioactive H³-hippuryl glycine 
glycine in young (8 weeks) and old (24 weeks) db/db mice and their controls (*P<0.01 




1. Measurement of Cardiovascular Parameters: 
Mean arterial pressure (MAP) and heart rate (HR) were monitored for 24 hours every 
week for 20 weeks. At early age (8-9 weeks) there was no difference in MAP between 
diabetic and control mice (Figure 1A), but showed a significant decrease in HR (Figure 
1B, P<0.01; n=6. MAP gradually increased with age in db/db diabetic mice compared to 
the controls (Figure 2). By 14-15 weeks MAP in diabetics increased compared to their 
lean controls both during day (101 ± 1 vs. 117 ± 2 mmHg) and night (110 ± 1.7 vs. 3.1 
mmHg) (Figure 2A; P<0.01, n=6). To investigate the role of AT1 receptor in mediating 
the increased BP in db/db mice, mice (7-8 weeks) were treated with AT1 blocker, 
losartan (10 mg/kg/day in drinking water for 20 weeks. Chronic treatment with losartan 
had no effect on the MAP in control animals (Figure 3, *P<0.01; n=6). However losartan 
significantly blocked the progressive increase in MAP in diabetic mice during day (102 ± 
4 vs. 117 ± 2.5 mmHg) and night (104 ± 4 vs. 126 ± 2.2 mmHg) (Figure 3, P<0.01; n=6).  
 
 
2. Measurement of blood glucose and plasma insulin: 
 
The basic animal characteristics are as shown in the Table 1. At 8 weeks age db/db 
diabetic mice gained more weight than their lean controls (33.5 ± 1.1 vs. 23.13 ± 0.32 
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gm, diabetic vs. control, P<0.01; n=6). At early age db/db mice showed the signs of 
diabetes and insulin resistance. Figure 4 shows that at a young age (8 weeks) the db/db 
mice had already demonstrated high blood glucose levels (315 ± 28 vs. 117 ± 0.3 mg/dl, 
diabetic vs. lean control, P<0.01; n=6) and high insulin levels (27 ± 2 vs. 1 ± 0.2 ng/dL, 
diabetic vs. lean control, P<0.01; n=6) (Table 1) when compared to their lean controls. 
By 14 weeks of age diabetic mice exhibited marked obesity, and pronounced 
hyperglycemia (550 ± 25 vs. 117.1 ± 0.5 ng/dL, diabetic vs. lean control, P<0.01; n=6) 
and hyperinsulinemia (4.5 ± 0.8 vs. 1.2 ± 0.25 ng/dL, diabetic vs. lean control, P<0.01; 
n=6) compared to their lean controls. The decrease in insulin levels from 8 weeks to 14 
weeks might be due to the insufficiency of the β cells of the pancreas to secrete more 
insulin. As shown in figure 5 there was an age dependent increase in blood glucose levels 
of db/db mice from 7 weeks to 35 weeks. The db/db mice survive more than 40 weeks of 
age and later die due to diabetic acute nephropathy or other cardiovascular complications 
of type2 diabetes. 
 
3. Optimization of ACE2 flouregenic assays: 
ACE2 flouregenic assays were optimized using two flouregenic substrates Mca-
YVADAPK [Dnp] and Mca-APK [Dnp]. Plasma (10 μl) and tissue extracts (50 mg 
protein) from ACE2 wild type (WT) and ACE2 knockout (KO) mice were incubated with 
Mca-YVADAPK [Dnp] and ACE2 activity was measured at different time points (Figure 
6). There was no difference between WT and KO kidney ACE2 activity after 20 min and 
6 hours incubation. In addition there was no detectable plasma and brain activity after 20 
min incubation. Unexpectedly, there was a significant plasma ACE2 activity after 6 hours 
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(Figure 7). This indicates that the substrate Mca-YVADAPK [Dnp] might not be a good 
substrate for measurement of ACE2 activity. To determine whether Mca-APK [Dnp] 
substrate was specific to ACE2 kidney lysate (50 μg protein) from ACE2 WT and ACE2 
KO was incubated in presence and absence of 100 Mm EDTA. No ACE2 activity was 
observed in ACE2 KO indicating the specificity and selectivity of Mca –APK [Dnp] to 
ACE2 (Figure 8). To study the effects of NaCl on ACE2 activity kidney lysate (50 μg 
protein) was incubated with Mca-APK [Dnp] in the presence of different concentrations 
of NaCl (0, 30, 300 Mm) (Figure 8) (Guy et al. 2003 ). Kidney ACE2 activity increased 
with increased concentrations of NaCl. (Figure 7) (Guy et al. 2003). Brain ACE2 activity 
in db/db diabetic mice and their lean controls was determined using the substrate Mca-
APK [Dnp] in the presence and absence of captopril (selective ACE inhibitor) and DX-
600 (selective ACE2 inhibitor). DX-600 significantly inhibited ACE2 activity indicating 
the specificity of the assay (Figure 9). Mca-APK [Dnp] substrate was used for ACE2 
activity assays. Effect of time on ACE2 activity was determined using Mca- APK Dnp] in 
plasma, liver and pancreas from 0-2.5 hours. There was a gradual increase in ACE2 
activity in the liver and pancreas with time and there was no detectable plasma ACE2 
activity (Figure 10). 
 
4. Measurement of ACE activity in young (8 weeks) mice:  
ACE activity was determined in plasma, kidney cortex, lung, and brain in young (8 
weeks) db/db diabetic mice and their age matched controls. At this age the db/db mice 
were hyperglycemic, hyperinsulinemic and normotensive at this age. Plasma ACE 
activity was markedly increased in db/db diabetic mice when compared to their lean 
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controls (Figure 11; (db/db 0.44 ± 0.11 U/μg protein vs. control 0.13 ± 0.09 U/μg 
protein, P<0.001; n=6). By contrast kidney ACE activity was significantly decreased in 
db/db diabetic mice compared to their lean littermates (Figure12; db/db 1.045 ± 0.09 
U/μg protein vs. control 0.048 ± 0.065 U/μg protein, P<0.01; n=6). Lung ACE activity 
was observed to be high but there is no significant difference observed between db/db 
mice and their controls (Figure 13; db/db 2.56 ± 0.83 U/μg protein vs. control 3.23 ± 0.4 
U/μg protein, n=6). There was no significant difference observed in brain ACE activity in 
db/db diabetic mice compared to their controls (Figure 14; db/db 0.42 ± 0.057 U/μg 
protein versus control 0.40 ± 0.042 U/μg protein, n=6). Significantly decreased ACE 
activity in young (8 weeks) db/db diabetic mice seems to be organ specific to the kidney.  
 
5. Measurement of ACE2 activity in young (8 weeks) db/db mice: 
Plasma, kidney, lung and brain ACE2 activity was determined in young (8 weeks) db/db 
diabetic mice and their lean littermates. Young db/db diabetic mice were normotensive, 
hyperglycemic and hyperinsulinemic. There was no detectable levels of plasma ACE2 
activity in db/db mice and their controls (Figure 11; n=6). Kidney ACE2 activity was 
significantly increased in the db/db diabetic mice when compared to the controls (Figure 
12; db/db 66.22 ± 0.9 pmol/hr/μg protein vs. control 43.68 ± 0.8 pmol/hr/μg protein, 
P<0.01; n=6). In lungs by contrast, there was no significant difference in ACE2 activity 
in both db/db diabetic mice and their lean controls (Figure 13; db/db 56.004 ± 0.16 
pmol/hr/μg protein vs. control 46.73 ± 0.14 pmol/hr/μg protein,  n=6 ). There was no 
significant difference in brain ACE2 activity between db/db mice and their lean controls 
(Figure 14; db/db 4.11 ± 0.17 pmol/hr/μg protein vs. control 4.19 ± 0.21 pmol/hr/μg 
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protein, n=6). A highly significant increase in ACE2 activity in db/db diabetic mice 
appears to be organ specific to the kidney at a young age (8 weeks). 
 
6. Summary of ACE and ACE2 activities in young mice (8 weeks) 
To summarize the plasma and tissue ACE activities in the young (8 weeks) db/db mice, 
there was a significantly increased plasma ACE activity and significantly decreased 
kidney ACE activity in db/db mice compared to the controls. However there was no 
significant difference in ACE activities in lung and brain between db/db mice and their 
controls (Figure 15). There were no detectable levels of plasma ACE2 in db/db mice and 
their controls (Figure 16). But there was a significantly increased kidney ACE2 in db/db 
mice compared to controls. In the lungs and brain there was no significant difference 
between db/db mice and their lean controls (Figure 16). 
 
7. Western Blot Analysis (young db/db mice): 
ACE and ACE2 protein expression levels in young mice (8 weeks) were quantified by 
western blot analysis. In kidney and lungs, a single band of protein was detected at 170 
kDa for ACE (Figures 17 and 18) and 90 kDa (Figures 19 and 20) for ACE2 when 
membranes were probed with respective antibodies. This result is consistent with the 
molecular weights of the enzymes ACE and ACE2, respectively as reported by others 
(Vickers et al. 2002b) (Eriksson et al. 2002). 
Kidney ACE protein expression was markedly reduced in db/db diabetic mice compared 
to their lean controls (Figure 17; db/db 0.83 ± 0.12 n=6 vs. control 1.52 ± 0.15 *P<0.01; 
n=6). Kidney ACE2 protein expression, by contrast, was increased significantly, in db/db 
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diabetic mice than in the lean controls (Figure 18; db/db 4.46 ± 0.11 n=6 vs. control 0.43 
± 0.16, *P<0.01 n=6). In lungs there was no significant difference between db/db diabetic 
mice and their controls in either ACE (Figure 19; db/db 0.25 ± 0.09 n=6 vs. control 0.27 
± 0.06, n=6) or ACE2 protein abundance (Figure 20; db/db 0.56 ± 0.17 n=6 vs. control 
0.78 ± 0.14, n=6). 
 
8. Measurement of ACE activity in old (24 weeks) db/db mice: 
To investigate the progressive changes in ACE activity in db/db mice at a later stage of 
type2 diabetes, plasma and kidney ACE activity were measured in 24 weeks old db/db 
diabetic mice and their lean controls. There was a significant increase in the kidney ACE 
activity in the old db/db mice when compared to the young mice (Figure 21, db/db old 
1.76 ± 0.147 U/ µg protein vs. db/db young 0.048 ± 0.047 U/ µg protein, *P<0.01, n=6). 
In the plasma there was a significant increase in ACE activity in the old db/db mice when 
compared to the young mice (Figure 22; db/db old 218.90 ± 6.7 U/L protein vs. db/db 
young 165.4 ± 9.1 U/L protein, *P<0.01, n=6).  
 
9. Measurement of ACE2 activity in old (24 weeks) db/db mice: 
ACE2 activity was measured in the kidney old mice (24 weeks) to study the changes in 
ACE2 levels at a later stage of type2 diabetes. There was a significant decrease in kidney 
ACE2 activity in the old db/db mice when compared to the young mice (Figure 22; db/db 
old 53.463 ± 1.57 U/ µg protein vs. db/db young 27.24 ± 1.30 U/ µg protein) *P<0.01, 
n=6. Increased ACE activity and decreased ACE2 activity was observed in db/db diabetic 









The RAS is a coordinated hormonal cascade and a central regulator of cardiovascular, 
renal and adrenal functions that regulate fluid and electrolyte balance and arterial 
pressure (Hackenthal et al. 1990). In addition, RAS plays a key role in the 
pathophysiology of various diseases of the cardiovascular and renal systems. The RAS is 
an attractive target for medications designed for management of cardiovascular 
dysfunction (Vickers et al. 2002a). ACE and ACE2 are the two primary components of 
RAS. The traditional view that Ang II is the key product of the RAS has been challenged 
with the recent discovery of a new carboxypeptidase, ACE2, and growing evidence for a 
physiological role of its peptide product, Ang (1-7)(Ferrario et al. 2005a). A recent report 
suggested that the deletion of the ACE2 gene leads to the development of Ang II 
dependent cardiovascular and renal damage (Oudit et al. 2006). It is the ability of ACE2 
to inactivate the vasoconstrictor, Ang II, and generate the putative cardio protective 
metabolite, Ang (1-7), that implicates ACE2 as an important participant in cardiovascular  
homeostasis (Guy et al. 2003). However no quantitative assessment has been made for 
the enzyme activity and protein expression of ACE and ACE2 and hence, it is of interest 
to characterize circulating and localized RAS especially in the kidney, brain and lungs. 
 
The aim of the present study is to examine the changes in blood pressure in relation to 
changes in ACE/ACE2 balance in murine models of type 2 diabetes mellitus. Murine 
models of type 2 diabetes (db/db) mice and their lean controls aged 8-20 weeks were 
used as a bioassay.  
 
 One of the features of the present study was the application of radio telemetry to measure 
the blood pressure and day/night rhythms in cardiovascular parameters in db/db and 
control mice. This method accurately monitors BP, heart rate, and locomotor activity in 
conscious, untethered, freely moving mice with minimum human interference. Diabetic 
(db/db) mice have been extensively studied as diabetic murine models but there is little 
information about blood pressure in measurements in these mice. Besides the scarcity of 
data, most of the available data was collected using the conventional tail- cuff method 
(Kosugi et al. 2006) (Guo et al. 2006) and also presents conflicting results, such as 
increased (Bagi et al. 2005;Guo et al. 2005b), decreased (Kosugi et al. 2006) or no 
changes in BP in db/db mice(Moriyama et al. 2004). This divergence in the results may 
be due to the differences in the animal age and also the methodology used to acquire 
blood pressure measurements in the previous data. The focal result of the present project 
is that diabetic db/db mice develop hypertension with age that is associated with changes 
in the balance of ACE/ACE2 activity and expression. 
 
Our data show that the BP is significantly increased in db/db mice with age (Figure 1 and 
2. Our data also show differences in BP, HR and locomotor activity in day/night pattern. 
The key issue is that the blood pressure in the night time is higher than in the day. There 
is clinical evidence that verifies a relationship between diabetes and BP rhythm 
perturbations {Carey, 2001 383 /id}. Diabetic patients present hypertension and reduced 
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gradient between light and dark BP levels (Jermendy et al. 1996). Although lean control 
mice were not hypertensive, this group showed, as expected, an increase in the blood 
pressure during the dark phase(Farah et al. 2000;Farah et al. 2004). In the present study 
diabetic db/db mice also presented differences in the BP levels between the light and dark 
phases. 
 
 The db/db diabetic mice have insulin resistance from an early age (8 weeks) serving as 
good models for type 2 diabetes mellitus. One of the goals of this project was to 
investigate BP control and the role of angiotensin AT1 receptors in the db/db model of 
type2 diabetes. Chronic treatment with losartan (10 mg/kg/day) significantly blocked the 
progression of the MAP changes in diabetic mice during the day and night (day 102 ± 4 
vs 117 ± 2.5 mmHg vs. night (104 ± 4 vs 126 ± 2.2 mmHg, P<0.01, n=6) (Figure 3). Our 
results document the increase in BP in db/db diabetic mice and the importance of Ang 
AT1 receptors in mediating the BP changes in this murine model of type 2 diabetes 
(Figure 3). There is a previous study showing the increase in blood glucose level after 
losartan was administered (Chu et al. 2006a). These findings provide a novel and at least 
partial explanation for the reduced incidence of type 2 diabetes related hypertension that 
has been observed in a number of clinical trials applying AT1R inhibition to individuals 
at high risk of cardiovascular problems during type 2 diabetes. 
 
Our hypothesis is that there is a change in balance of ACE and ACE2 during the course 
of diabetes in db/db diabetic mice. In the present study, we investigated ACE and ACE2 
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enzyme activity and protein expression in plasma, kidney and lungs from young (8 
weeks) and old (24 weeks) db/db diabetic mice and age matched lean controls.  
There is previous data that shows that chloride ions affect the enzyme activity of ACE2 
(Oudit et al. 2003). Therefore we optimized the ACE2 activity assays and decided to 
perform the assays under identical conditions that closely mimic the salt concentration 
and pH of the extra cellular environment (i.e. 300mM NaCl and pH 7.4) {Wysocki et al., 
2006). In a recent study using db/db and streptozocin diabetic mice an alteration in ACE 
and ACE2 activities were observed compared to non-diabetic controls (Wysocki et al. 
2006). Assays to measure ACE activity use spectrophotometric, flouremetric, high-
performance liquid chromatography, or radiometric approaches and are quite reliable, but 
there is limited information on ACE2 assays (Danilczyk et al. 2003). There is a recent 
study that used SELDI-TOF MS approach to measure plasma ACE and Ang II levels. 
(Elased et al. 2005). Previously ACE2 activity has been previously measured using two 
flouregenic substrate, Mca-YVADAPK [Dnp] (Wysocki et al. 2006) and Mca-APK[Dnp] 
(Herath et al. 2007). ACE2 activity assays were optimized using both of these substrates. 
With Mca-YVADAPK [Dnp] substrate no difference in ACE2 activity between kidney 
WT and KO mice was observed indicating that the substrate is not specific to ACE2 
(Figure 8) . There is no evidence for the presence of ACE2 in the plasma. Using Mca-
YVADAPK [Dnp] substrate we found high ACE2 activity in the plasma (Figure 8). We 
have shown that Mca-YVADAPK [Dnp] has less specificity and suitability for ACE2.  We 
developed an assay to measure tissue ACE2 activity specifically using 7-Mca-APK 
[Dnp]. The selective cleavage of this substrate by ACE2 allowed us to measure ACE2 
activity. The specificity and selectivity of this substrate to ACE2 was confirmed by our 
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experiments with ACE2 KO mice and by using a metalloprotease inhibitor, EDTA In 
ACE2 KO mice there was no ACE2 activity observed and in ACE2 WT a significant 
increase in ACE2 activity was observed indicating that the substrate 7-Mca-APK [Dnp] is 
highly selective to ACE2 (Figure 9). Brain ACE2 activity in db/db diabetic mice and 
their lean controls was determined using the substrate Mca-APK [Dnp] in the presence 
and absence of captopril (selective ACE inhibitor) and DX-600 (selective ACE2 
inhibitor). DX-600 significantly inhibited ACE2 activity indicating the specificity of the 
assay (Figure 10). Mca-APK [Dnp] substrate was used for ACE2 activity assays. Hence 
ACE2 assays were conducted using Mca-APK [Dnp] substrate for measuring plasma and 
tissue ACE2 activity. Measurement of circulating forms of ACE2 has proved 
problematic. In normal plasma, there was no detectable ACE2 activity (Figure 12). A 
recent clinical trial showed that plasma ACE2 was only detectable in 10% of individuals, 
a total study population of 500 (Rice et al. 2006).  
 
In a recent study it was shown that increased ACE2 and decreased ACE protein in young 
db/db mice acted as renoprotective combination (Ye et al. 2004). We have shown that 
there is a significant increase in kidney ACE2 activity and protein expression in db/db 
mice compared to their controls (Figure 13, 19; P<0.01). Kidney ACE protein 
expression, by contrast, was significantly decreased in young (8-9 weeks) normotensive 
db/db diabetic mice compared to their non-diabetic controls. The reduction of ACE 
protein activity and expression coupled with augmentation of ACE2 protein activity and 
expression in young db/db diabetic mice was tissue specific. In lungs there was no 
significant difference between db/db mice and their lean controls. In plasma by contrast 
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we observed significantly increased ACE activity and practically no ACE2 activity; 
Figure 12 (A) and (B). This agrees with previous studies performed by using SELDI-
TOF-MS technique (Elased et al. 2006). This is the first report to show that there is 
significant increase in plasma ACE activity in db/db diabetic mice.  
Western blot analysis was performed to investigate ACE and ACE2 protein expression in 
the kidney, lungs and the brain from young db/db mice (8 weeks) old. We have shown 
that that in 8-9 weeks db/db diabetic mice there was a significant increased kidney ACE2 
protein  compared to the controls (Figure 22,P<0.01). ACE protein expression, by 
contrast, was significantly decreased in kidney from db/db mice compared with their non-
diabetic controls (Figure 21, P<0.01). The reduction of tissue ACE protein expression 
and increase in ACE2 protein expression was tissue specific. In the lungs there was no 
significant difference in ACE and ACE2 protein expression. There was a good 
correlation between ACE and ACE2 enzymatic activity and the protein expression in the 
kidney, lungs and brain. The down regulation of ACE and the up regulation of ACE2 in 
the kidney is an intrigue finding. The mechanism for tissue specific changes in ACE2 
activity is unknown, but it seems reasonable to speculate that it could be, directly or 
indirectly, a consequence of hyperglycemia and insulin resistance. The fact that the up 
regulation of ACE2 is organ specific (renal tissue but not the lungs) argues however 
against a generalized effect of hyperglycemia on ACE2.  
In the old (24 weeks) db/db mice ACE2 enzyme activity has significantly decreased in 
the kidney (Figure 23; P<0.01). ACE enzyme activity by contrast has increased 
significantly when compared to the young db/db mice (Figure 22 P<0.01). On the basis 
of these findings we can infer that the increase in ACE may result in increased local 
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levels of Ang II leading to hypertension. In the plasma, ACE enzyme activity was even 
higher compared to young db/db mice (Figure 24; P<0.01). Hence by this we can infer 
that the increase in circulating ACE can be the primary reason for increase in blood 
pressure at a late stage of diabetes. We speculate that this pattern of decreased ACE2 
activity coupled with increased ACE may be the primary cause of hypertension and 
might lead to various cardiovascular dysfunctions. A high level of ACE2 in the young 
db/db mice prevents Ang II accumulation while favoring Ang (1-7) formation. ACE2 has 























The counterbalancing role of ACE and ACE2 in the RAS and their involvement in 
controlling the blood pressure and electrolyte balance is gaining credence. ACE2 has 
been implicated in a number of disease conditions including hypertension, diabetes and 
cardiac dysfunction. Most recently structural solutions of both ACE and ACE2 should 
facilitate further design of potent and selective ACE inhibitors. The findings in the 
present study have answered some of the questions as to how cardiovascular parameters 
are affected by changes in ACE/ACE2 balance in different stages of type2 diabetes 
mellitus.  
Results show that the db/db diabetic mice are hyperglycemic and hyperinsulinemic at a 
young age (8 weeks). db/db diabetic mice are good animal models for type 2 diabetes. 
The data from the project implicates that there is a progressive increase in the blood 
pressure in db/db mice showing that these mice become hypertensive as type 2 diabetes 
progresses from 14-15 weeks of age. The reduction of the blood pressure in losartan 
treated mice helps us to understand the critical role of Angiotensin ATI receptors in 
mediating BP changes in diabetic db/db mice. Antihypertensive agents such as 
Angiotensin receptor blockers (ARBs) might be a valuable therapeutic approach for the 
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treatment of diabetes induced cardiovascular complications as well as diabetic 
nephropathy. 
We have also shown that in the young db/db mice, there is a profound reduction in the 
ACE protein expression and enzyme activity in the kidney, whereas ACE2 protein 
expression is increased at early stage of diabetes. It seems reasonable to propose that such 
a combination would attenuate angiotensin II formation and could exert a protective 
effect against the development of hypertension controlling increase in BP at early stages 
of type2 diabetes and probably against the development of nephropathy. This kind of 
pattern of ACE/ACE2 was observed to be tissue specific to the kidney during the course 
of type2 diabetes in 8-20 weeks old db/db mice. Decreased ACE2 activity and protein 
expression and increased ACE activity might be the sole reason for Ang II accumulation, 
increase in blood pressure and end stage renal disease at a later stage of diabetes mellitus. 
We have also shown that there is a significant increase in circulating ACE in db/db 
diabetic mice. ACE2, on the contrast is completely localized in the tissues. Our project 
has given a novel and a partial explanation as to how the different components of RAS 
are regulated in different stages of type2 diabetes. As the complexity of this crucial 
pathway is unraveled, there is growing interest in the therapeutic potential of agents that 











Role of angiotensin AT1 receptors in the development of cardiovascular dysfunction 
in type 2 diabetic (db/db) mice 
 
Keerthy Kanakamedala, Danielle Senador, Yanfang Chen, Mariana Morris, Khalid. M. 
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Wright State University Boonshoft School of Medicine, Dayton, OH 
 
 
Cardiovascular disease is a long term complication of diabetes, which remains a leading 
cause of mortality and morbidity. There is evidence for activation of the renin angiotensin 
system (RAS) in diabetic animals and humans. We have shown previously that a high 
fructose diet in mice produces glucose tolerance and increased blood pressure (BP). This 
goal of this study was to investigated BP control and the role of the angiotensin AT1 
receptors in the db/db model of type 2 diabetes. Mice (8-9 weeks) were implanted with 
carotid telemetric probes and 24 hr mean arterial pressure (MAP), heart rate (HR) and 
activity was monitored every week for up to 20 weeks. At early age (9-10 weeks), db/db 
mice developed significant hyperglycemia and hyperinsulinemia which was not 
associated with changes in MAP. HR and activity were decreased. MAP gradually 
increased with age in db/db diabetic mice. By 12 weeks MAP in diabetics was higher as 
compared to their lean controls both during day (101 ± 1 vs 117 ± 2 mmHg, p<0.01) and 
night (110 ± 1.7 vs 121 ± 3.1 mmHg, p<0.01). Chronic treatment with losartan (10 
mg/kg/day in drinking water) for 12 weeks significantly blocked the progression of the 
MAP changes in diabetic mice during day (102 ± 4 vs 117 ± 2.5 mmHg, p<0.01) and 
night (104 ± 4 vs 126 ± 2.2 mmHg, p<0.01). Results document the increase in BP in 
db/db diabetic mice and the importance of Ang AT1 receptors in mediating the BP 
changes in this murine model of type 2 diabetes. 
 












Increased ACE activity in young normotensive diabetic (db/db) mice 
Keerthy Kanakamedala, Danielle Senador, Wenfeng Zhang, Mariana Morris,  
Khalid. M. Elased 
Wright State University Boonshoft School of Medicine, Dayton, OH 
 
There is evidence for activation of the renin angiotensin system (RAS) in some diabetic 
animals and humans. Emerging evidence shows that the vasoconstrictor actions of Ang II 
may be opposed by formation of the vasodilator, Ang- (1-7), partly generated by action of 
angiotensin converting enzyme 2 (ACE2). Recent studies showed increased ACE2 and 
decreased ACE protein in 8 weeks db/db mice. However, the role of ACE2 in diabetes, 
hypertension and renal disease is currently in the early phases of investigation. The aim 
of this study was to investigate the role of diabetes in triggering an increase in blood 
pressure (BP) and changes in ACE and ACE2 indices in db/db diabetic mice. Mice (7-8 
weeks) were implanted with carotid telemetric probes for measurement of BP. 
Conventional and Surface Enhanced Laser Desorption/Ionization Mass Spectrometry 
(SELDI-TOF-MS) were used to evaluate plasma, tissue and urine ACE and ACE2 
activity. At young age (8-9 weeks), db/db mice developed hyperglycemia and 
hyperinsulinemia which was not associated with changes in BP. Unexpectedly in young 
normotensive mice there was a highly significant increase in plasma ACE activity in 
db/db mice compared to controls (P<0.001, n=6). In contrast kidney ACE and ACE2 
activities were significantly decreased in young normotensive mice (P<0.05, n=6). 
SELDI-TOF-MS data in plasma demonstrated the formation of a peak corresponding to 
Ang II (1045, M/Z) indicating ACE activity. In addition there was no peak corresponding 
to Ang- (1-7) (899, M/Z), indicating no detectable plasma ACE2 using SELDI-TOF-MS 
analysis. There was a significant increase in ACE2 activity in db/db urinary spot samples 
compared to controls. Western blot analysis show decreased kidney ACE1 and increased 
ACE2 in hypertensive db/db mice (P<0.05, n=6). Immunofluorescence study of ACE1 
and ACE2 in kidney glomeruli showed increased ACE1 and decreased ACE2 staining in 
hypertensive diabetic mice compared to normal controls. Conclusion: 1) this is the first 
report of increased plasma ACE activity in db/db mice, 2) loss of ACE2 in urine and 
reduced kidney ACE2 protein could contribute to diabetes-induced hypertension, 3) 
ACE2 may play a compensatory mechanism against development of hypertension in 
db/db mice. 
 








Activation of Renin Angiotensin System Caused High Blood Pressure in (db/db) 
Diabetic Mice. 
 
Danielle Senador, Keerthy Kanakamedala, Wenfeng Zhang, Yanfang Chen, Mariana 
Morris, Khalid. M. Elased 
 
 Wright State University Boonshoft School of Medicine, Dayton, OH 
 
Cardiovascular disease is a long term complication of diabetes, which remains a leading 
cause of mortality and morbidity. The goal of this study was to unravel the role of renin 
angiotensin system (RAS) in the control of cardiovascular parameters in db/db model of 
type 2 diabetes. Mice (8-9 weeks) were implanted with carotid telemetric probes and 24 
hr mean arterial pressure (MAP), heart rate (HR) and activity was monitored every week 
for up to 15 weeks. At early age (8-10 weeks), db/db mice developed significant 
hyperglycemia and hyperinsulinemia which was not associated with changes in MAP. By 
12 weeks MAP in diabetics was higher as compared to their lean controls both during day 
(101 ± 1 vs 117 ± 2 mmHg, p<0.01) and night (110 ± 1.7 vs 121 ± 3.1 mmHg, p<0.01). 
Chronic treatment with losartan (10 mg/kg/day in drinking water) for 12 weeks 
significantly blocked the progression of the MAP changes in diabetic mice during day 
(102 ± 4 vs 117 ± 2.5 mmHg, p<0.01) and night (104 ± 4 vs 126 ± 2.2 mmHg, p<0.01). 
Surface Enhanced Laser Desorption/Ionization Mass Spectrometry (SELDI-TOF-MS) 
was used to evaluate RAS enzyme activity. Plasma aliquots (1 µl) from normal and 14 
weeks old db/db-diabetic mice were added to 50 µl MES buffer (50 mM, pH 6.5 ) 
containing bestatin and PMSF, spiked with Ang I (1296, M/Z) and incubated for 2 hours 
at 37oC. Protein Chips (CM10) were spotted with 1µl of the reaction mixture and 
analyzed. Results demonstrated the formation of peak corresponding to Ang II (1045, 
M/Z) indicating angiotensin converting enzyme (ACE1) activity. However there was no 
peak corresponding to Ang 1-7 (899, M/Z) indicating no detectable plasma ACE2 in both 
groups. There was a significant increase in plasma ACE activity in db/db-diabetics 
compared to controls (p<0.05, n=6). Results document: 1) increase of BP in db/db 
diabetic mice, 2) importance of Ang AT1 receptors and plasma ACE1 in mediating the 
BP changes in this model of type 2 diabetes, 3) potential for using SELDI-TOF-MS to 
study the processing of angiotensin peptides. 
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